The survival effect of intact CDKN2A/B in IDH-wt gliomas quantitatively reaches that of the survival benefit of the addition of temozolomide to radiotherapy in the “Stupp” trial in GBM (HR = 0.63) [37]. This evidence concerns the gene CDKN2A and glioblastoma.